174 related articles for article (PubMed ID: 25719487)
21. Real-time trafficking and signaling of the glucagon-like peptide-1 receptor.
Roed SN; Wismann P; Underwood CR; Kulahin N; Iversen H; Cappelen KA; Schäffer L; Lehtonen J; Hecksher-Soerensen J; Secher A; Mathiesen JM; Bräuner-Osborne H; Whistler JL; Knudsen SM; Waldhoer M
Mol Cell Endocrinol; 2014 Feb; 382(2):938-49. PubMed ID: 24275181
[TBL] [Abstract][Full Text] [Related]
22. Synthesis and evaluation of optical and PET GLP-1 peptide analogues for GLP-1R imaging.
Behnam Azad B; Rota V; Yu L; McGirr R; St Amant AH; Lee TY; Dhanvantari S; Luyt LG
Mol Imaging; 2015; 14():. PubMed ID: 25762192
[TBL] [Abstract][Full Text] [Related]
23. Dual-purpose linker for alpha helix stabilization and imaging agent conjugation to glucagon-like peptide-1 receptor ligands.
Zhang L; Navaratna T; Liao J; Thurber GM
Bioconjug Chem; 2015 Feb; 26(2):329-37. PubMed ID: 25594741
[TBL] [Abstract][Full Text] [Related]
24. In vivo imaging of transplanted islets with 64Cu-DO3A-VS-Cys40-Exendin-4 by targeting GLP-1 receptor.
Wu Z; Todorov I; Li L; Bading JR; Li Z; Nair I; Ishiyama K; Colcher D; Conti PE; Fraser SE; Shively JE; Kandeel F
Bioconjug Chem; 2011 Aug; 22(8):1587-94. PubMed ID: 21692471
[TBL] [Abstract][Full Text] [Related]
25. Radiopeptide imaging and therapy in Europe.
Ambrosini V; Fani M; Fanti S; Forrer F; Maecke HR
J Nucl Med; 2011 Dec; 52 Suppl 2():42S-55S. PubMed ID: 22144555
[TBL] [Abstract][Full Text] [Related]
26. Evaluation of
Kimura H; Ogawa Y; Fujimoto H; Mukai E; Kawashima H; Arimitsu K; Toyoda K; Fujita N; Yagi Y; Hamamatsu K; Murakami T; Murakami A; Ono M; Nakamoto Y; Togashi K; Inagaki N; Saji H
Bioorg Med Chem; 2018 Jan; 26(2):463-469. PubMed ID: 29273416
[TBL] [Abstract][Full Text] [Related]
27. [111In-pentetreotide in the study of tumors expressing somatostatin receptors].
Mateos Fernández J; Pons Pons F; Fuster Pelfort D; Vidal-Sicart S; Lomeña Caballero F; Herranz García-Romero R
Rev Esp Med Nucl; 1999 Oct; 18(5):325-30. PubMed ID: 10562660
[TBL] [Abstract][Full Text] [Related]
28. The peptide-hormone glucagon-like peptide-1 activates cAMP and inhibits growth of breast cancer cells.
Ligumsky H; Wolf I; Israeli S; Haimsohn M; Ferber S; Karasik A; Kaufman B; Rubinek T
Breast Cancer Res Treat; 2012 Apr; 132(2):449-61. PubMed ID: 21638053
[TBL] [Abstract][Full Text] [Related]
29. In vivo imaging of the glucagonlike peptide 1 receptor in the pancreas with 68Ga-labeled DO3A-exendin-4.
Selvaraju RK; Velikyan I; Johansson L; Wu Z; Todorov I; Shively J; Kandeel F; Korsgren O; Eriksson O
J Nucl Med; 2013 Aug; 54(8):1458-63. PubMed ID: 23761918
[TBL] [Abstract][Full Text] [Related]
30. Glucagon-like peptide (GLP)-1(9-36)amide-mediated cytoprotection is blocked by exendin(9-39) yet does not require the known GLP-1 receptor.
Ban K; Kim KH; Cho CK; Sauvé M; Diamandis EP; Backx PH; Drucker DJ; Husain M
Endocrinology; 2010 Apr; 151(4):1520-31. PubMed ID: 20172966
[TBL] [Abstract][Full Text] [Related]
31. Tumor imaging and therapy using radiolabeled somatostatin analogues.
de Jong M; Breeman WA; Kwekkeboom DJ; Valkema R; Krenning EP
Acc Chem Res; 2009 Jul; 42(7):873-80. PubMed ID: 19445476
[TBL] [Abstract][Full Text] [Related]
32. Glucagon acts through its own receptors in the presence of functional glucagon-like peptide-1 receptors on hamster insulinoma.
Marie JC; Boissard C; Skoglund G; Rosselin G; Breant B
Endocrinology; 1996 Oct; 137(10):4108-14. PubMed ID: 8828464
[TBL] [Abstract][Full Text] [Related]
33. Evaluation of the Influence of the Conjugation Site of the Chelator Agent HYNIC to GLP1 Antagonist Radiotracer for Insulinoma Diagnosis.
Faintuch BL; Seo D; de Oliveira EA; Targino RC; Moro AM
Curr Radiopharm; 2017; 10(1):65-72. PubMed ID: 28164753
[TBL] [Abstract][Full Text] [Related]
34. Expression of glucagon-like Peptide 1 receptor and its effects on biologic behavior in pancreatic neuroendocrine tumors.
Cases AI; Ohtsuka T; Fujino M; Ideno N; Kozono S; Zhao M; Ohuchida K; Aishima S; Nomura M; Oda Y; Mizumoto K; Tanaka M
Pancreas; 2014 Jan; 43(1):1-6. PubMed ID: 24326362
[TBL] [Abstract][Full Text] [Related]
35. Activation of glucagon-like peptide-1 receptor inhibits growth and promotes apoptosis of human pancreatic cancer cells in a cAMP-dependent manner.
Zhao H; Wei R; Wang L; Tian Q; Tao M; Ke J; Liu Y; Hou W; Zhang L; Yang J; Hong T
Am J Physiol Endocrinol Metab; 2014 Jun; 306(12):E1431-41. PubMed ID: 24801389
[TBL] [Abstract][Full Text] [Related]
36. Imaging tumors with peptide-based radioligands.
Behr TM; Gotthardt M; Barth A; Béhé M
Q J Nucl Med; 2001 Jun; 45(2):189-200. PubMed ID: 11476170
[TBL] [Abstract][Full Text] [Related]
37. 68Ga-DOTA-Exendin PET-MRI Fusion Imaging in a Case of Insulinoma.
Sood A; Basher RK; Kang M; Shukla J; Behera A; Walia R; Nada R; Mittal BR; Bhattacharya A
Clin Nucl Med; 2019 Jul; 44(7):e428-e430. PubMed ID: 31107750
[TBL] [Abstract][Full Text] [Related]
38. Molecular imaging in the investigation of hypoglycaemic syndromes and their management.
Pattison DA; Hicks RJ
Endocr Relat Cancer; 2017 Jun; 24(6):R203-R221. PubMed ID: 28400403
[TBL] [Abstract][Full Text] [Related]
39. Innovative imaging of insulinoma: the end of sampling? A review.
Christ E; Antwi K; Fani M; Wild D
Endocr Relat Cancer; 2020 Apr; 27(4):R79-R92. PubMed ID: 31951592
[TBL] [Abstract][Full Text] [Related]
40. Radiopeptides for Imaging and Therapy: A Radiant Future.
Chatalic KL; Kwekkeboom DJ; de Jong M
J Nucl Med; 2015 Dec; 56(12):1809-12. PubMed ID: 26514175
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
